The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalCOVID-19 & CancerTrials & Tribulations

COVID and lung cancer: How experts in cancer and virology joined forces in a challenging time

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage is available here.

Researchers from Icahn School of Medicine at Mount Sinai was recently awarded a U54 grant ($3.9 million over the first two years as a part of a five-year research proposal) to establish a NCI/SeroNet Center for Serological Excellence at Mount Sinai with a focus on lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Fred R. Hirsch, MD, PhD
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
By Ashley Cannon
Byline
Fred R. Hirsch, MD, PhD
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account